PARP2
ENSG00000129484
Target class
Enzyme
Chromosome
14
Approved drugs
7
Clinical candidates (approved and in development)
12
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Other names
- ARTD2
- Target name
- PARP2
- Gene name
- Poly(ADP-ribose) polymerase 2
- Gene symbol
- PARP2
- Previous gene symbols
- ADPRTL2
- Protein name
- Poly [ADP-ribose] polymerase 2 (PARP-2) (hPARP-2) (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 2) (ARTD2) (DNA ADP-ribosyltransferase PARP2) (EC 2.4.2.-) (NAD(+) ADP-ribosyltransferase 2) (ADPRT-2) (Poly[ADP-ribose] synthase 2) (pADPRT-2) (Protein poly-ADP-ribosyltransferase PARP2) (EC 2.4.2.-)
- Gene biotype
- Protein coding
- Gene family
- Poly(ADP-ribose) polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 79.61
- Tissue specificity (Gini)
- 0.259
- Tissue specificity (tau)
- 0.68
- KEGG gene identifiers
- hsa:10038
- Protein interaction confidence
- 0.839318
- Protein interaction partners
- 44
- R-HSA-110362
- R-HSA-5685939
- R-HSA-5696394
- R-HSA-5696395
- R-HSA-5696400
- End position
- 20357905
- Start position
- 20343601
- Chromosome
- 14
- Strand
- Forward
- Nucleus . Chromosome . Note=Recruited to DNA damage sites in a PARP1-dependent process: recognizes and binds poly-ADP-ribose chains produced by PARP1 at DNA damage sites via its N-terminus, leading to its recruitment. .
- Nucleoli
- Nucleoplasm
- PubMed 10364231
- PubMed 26704974
- PubMed 30104678
- PubMed 30321391
- PubMed 32939087
- PubMed 33141820
- PubMed 35349716
- Tissue specificity (tau)
- 0.679857
- Expression inequality (Gini)
- 0.25888
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 79.61
- Brain - Cerebellum
- 73.57
- Testis
- 45.77
- Cells - EBV-transformed lymphocytes
- 43.57
- Ovary
- 43.36
Expression in transcripts per million
- Brain - Cerebellar Hemisphere79.61
- Brain - Cerebellum73.57
- Testis45.77
- Cells - EBV-transformed lymphocytes43.57
- Ovary43.36
- Nerve - Tibial42.56
- Uterus42.08
- Brain - Frontal Cortex (BA9)39.35
- Cervix - Endocervix38.22
- Pituitary36.76
- Brain - Cortex36.5
- Cervix - Ectocervix34.93
- Thyroid32.91
- Fallopian Tube31.68
- Colon - Sigmoid28.91
- Breast - Mammary Tissue28.26
- Adipose - Subcutaneous27.19
- Skin - Sun Exposed (Lower leg)26.94
- Vagina26.34
- Brain - Nucleus accumbens (basal ganglia)25.42
- Skin - Not Sun Exposed (Suprapubic)25.15
- Artery - Aorta25.02
- Artery - Tibial25
- Spleen24.95
- Esophagus - Gastroesophageal Junction24.71
And 29 more, listed on the interactive page.
- GO:0006281
- GO:0006974
- GO:0030592
- GO:0070212
- GO:0070213
- GO:0140861
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0005730
- GO:0090734
- GO:0003682
- GO:0003684
- GO:0003950
- GO:0005515
- GO:0031491
- GO:0072572
- GO:0140294
- GO:0140805
- GO:0140806
- GO:0140807
- GO:0160004
- GO:1990404
Related records
Trials (940)
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
- A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
- A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
- A Dye for the Detection of Cancer of the Tongue and Mouth
- A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Drugs (12)
- 2X-121 Poly [ADP-ribose] polymerase 2 inhibitor
- E-7016 PARP 1, 2 and 3 inhibitor
- Niraparib Poly [ADP-ribose] polymerase 2 inhibitor
- Niraparib tosylate monohydrate Poly [ADP-ribose] polymerase 2 inhibitor
- Olaparib PARP 1, 2 and 3 inhibitor
- Pamiparib Poly [ADP-ribose] polymerase 2 inhibitor
- Rucaparib PARP 1, 2 and 3 inhibitor
- Rucaparib camsylate PARP 1, 2 and 3 inhibitor
- Senaparib Poly [ADP-ribose] polymerase 2 inhibitor
- Talazoparib Poly [ADP-ribose] polymerase 2 inhibitor
- Talazoparib tosylate Poly [ADP-ribose] polymerase 2 inhibitor
- Veliparib PARP 1, 2 and 3 inhibitor